Bausch & Lomb Americas Inc.
Pharmaceutical & medical device company payment data from CMS Open Payments.
Total Payments
$43.3M
Doctors Paid
35,986
Transactions
201,802
2024 Total
$15.5M
Payment Breakdown by Category
Research$13.3M (30.7%)
Food & Beverage$7.4M (17.0%)
Consulting$5.6M (12.9%)
Royalty/License$2.6M (6.0%)
Travel$2.1M (4.9%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $13.3M | 946 | 30.7% |
| Compensation for serving as faculty or as a speaker for a medical education program | $10.4M | 4,235 | 24.0% |
| Food and Beverage | $7.4M | 184,325 | 17.0% |
| Consulting Fee | $5.6M | 2,220 | 12.9% |
| Royalty or License | $2.6M | 77 | 6.0% |
| Travel and Lodging | $2.1M | 7,639 | 4.9% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $1.5M | 196 | 3.4% |
| Grant | $355,950 | 28 | 0.8% |
| Education | $68,581 | 2,099 | 0.2% |
| Space rental or facility fees (teaching hospital only) | $24,842 | 14 | 0.1% |
| Charitable Contribution | $10,000 | 2 | 0.0% |
| Long term medical supply or device loan | $8,580 | 16 | 0.0% |
| Gift | $5,303 | 5 | 0.0% |
Payments by Type
General
$30.0M
200,856 transactions
Research
$13.3M
946 transactions
Research Studies & Clinical Trials
| Study Name | Total Paid | Doctors | Records |
|---|---|---|---|
| A Multi-Center, Double-Masked, Randomized, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution, Used Two Times Daily in Healthy | $2.4M | 4 | 52 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION | $1.4M | 1 | 57 |
| A Multicenter, Double-Masked, Randomized, Placebo-Controlled Phase 3 Study of the Safety and Efficacy of Atropine 0.1% and 0.01% Ophthalmic Solutions Administered With a Microdose Dispenser for the Reduction of Pediatric Myopia Progression | $1.3M | 1 | 161 |
| A Safety and Effectiveness Study of a Contact Lens Cleaning and Disinfecting Solution | $1.1M | 1 | 137 |
| A Multi-Center, Double-Masked, Randomized, Active-Controlled, Parallel-Group Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% Preservative-Free Formulation with Lumify 0.025% in Adult Subjects with Ocular Redness | $1.1M | 2 | 49 |
| A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled Evaluation of the Onset and Duration of Action of the Combination Drug Product Brimonidine Tartrate 0.025% / Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to its Components and Vehicle in an Allergen BioCube (ABC) Clinical Trial in Subjects with Seasonal Allergic Conjunctivitis | $1.1M | 0 | 26 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, ACTIVE-CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION | $976,671 | 1 | 89 |
| A Study to Evaluate the Product Performance of a New Silicone Hydrogel Multifocal Contact Lens | $712,425 | 2 | 81 |
| A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled Evaluation of the Onset and Duration of Action of the Combination Drug Product Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution Compared to its Components and Vehicle for the Treatment of Allergic Conjunctivitis in the Conjunctival Allergen Challenge Model | $609,741 | 0 | 18 |
| A STUDY TO DOCUMENT THE SAFETY AND EFFECTIVENESS OF A NEW COHESIVE OVD WHEN COMPARED TO A CONTROL OVD | $459,730 | 0 | 58 |
| Study to Evaluate Safety and Effectiveness of the Boston Orthokeratology (oprifocon A) Shaping Lens in the Arise Orthokeratology Lens Design with Non-spherical Posterior Peripheral Curves | $374,148 | 0 | 46 |
| A Phase 1/2 study of Visudyne (liposomal verteporfin) in persons with recurrent high grade EGFR-mutated glioblastoma | $299,199 | 0 | 2 |
| POST-APPROVAL FOLLOW-UP STUDY OF THE IC-8 APTHERA IOL | $247,644 | 0 | 32 |
| A Study to Investigate the Safety and Effectiveness of the TENEO 317 Model 2 (1.28 US) Excimer Laser for Laser In Situ Keratomileusis (LASIK) Surgery to Treat Hyperopia With or Without Astigmatism | $180,012 | 0 | 20 |
| The study of transepithelial photoreactive keratectomy (PRK) treatment of patients with low to moderate myopia or hyperopia and up to +3.0 D of cylinder with the TENEO model 2 excimer laser | $153,000 | 0 | 12 |
| A PROSPECTIVE, MULTICENTER, RANDOMIZED, MASKED, ACTIVE CONTROLLED CLINICAL STUDY TO EVALUATE THE SAFETY AND EFFECTIVENESS OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TRIFOCAL INTRAOCULAR LENS IN SUBJECTS UNDERGOING CATARACT EXTRACTION. | $132,300 | 0 | 15 |
| The Impact of Trainee Involvement in Cataract Surgery in the Veterans Health Administration Medical System | $96,250 | 0 | 1 |
| A Prospective, Single-Center, Randomized Clinical Investigation to Evaluate the Performance of enVista Aspire (EA) Intraocular Lens against a Control and an Active-Comparator in Subjects Undergoing Cataract Extraction and Implantation of an Intraocular Lens | $78,072 | 2 | 12 |
| A STUDY TO INVESTIGATE THE SAFETY AND EFFECTIVENESS OF THE TECHNOLAS? TENEO 317 MODEL 2 EXCIMER LASER FOR LASER IN SITU KERATOMILEUSIS (LASIK) SURGERY TO TREAT MYOPIA OR MYOPIC ASTIGMATISM | $73,911 | 0 | 18 |
| Retrospective Chart Review of the Use of Lotemax SM in Refractive Surgery | $67,750 | 3 | 5 |
| A Single-Center Randomized Double-Masked Placebo Controlled Parallel-Group, Study of the Effects and Safety of 5% lifitegrast Ophthalmic Solution in Subjects with Dry Eye Disease in Ocular Graft-versus- Host Disease | $60,141 | 1 | 1 |
| A Non-interventional, Prospective, Multicenter, Single Arm, Post-Marketing Clinical Study to Evaluate the enVista Aspire (EA) Intraocular Lens in Subjects Undergoing Cataract Extraction | $57,122 | 0 | 17 |
| Influence of MIEBO on corneal tomography and biometry 1 hour after instillation | $48,130 | 0 | 2 |
| Evaluation of Perfluorhexylocatane Eyedrops in Habitual Contact Lens Wearers | $46,000 | 0 | 1 |
| Collect retrospective clinical data on patients implanted with either Pre Vue or Clareon IOL. Clinical data should include monocular and binocular visual acuities (UDVA, UlV A, COVA, DCIV /\.) and subjective quality of vision evaluations. These data points should be collected at various timepoints from preop to 1 month postop. | $40,000 | 0 | 1 |
| IC-8 APTHERA IOL NEW ENROLLMENT POST APPROVAL STUDY | $31,910 | 1 | 16 |
| A MULTICENTER, DOUBLE-ARM, PATIENT AND ASSESSOR-MASKED, PROSPECTIVE, RANDOMIZED CLINICAL TRIAL TO COMPARE VISUAL PERFORMANCE OF NEGATIVE AND NEUTRAL ASPHERIC MONOFOCAL INTRAOCULAR LENSE | $30,000 | 0 | 1 |
| Retrospective Chart Review of the Use of Vyzulta in Switch Patients | $28,500 | 4 | 7 |
| Phase III Presbyopia Correction using the VIS Optimal Keratoplasty (Opti-K) System | $26,765 | 0 | 1 |
| A PROSPECTIVE, MULTICENTER, POST MARKET OBSERVATIONAL STUDY TO EVALUATE ROTATIONAL STABILITY AND FUNCTIONAL VISUAL ACUITY OF THE ENVISTA ONE-PIECE HYDROPHOBIC ACRYLIC TORIC IOL MX60ET FOLLOWING CATARACT SURGERY | $22,313 | 0 | 4 |
Payments by Medical Specialty
Top Paid Doctors
| Doctor | Specialty | Location | Total | 2024 |
|---|---|---|---|---|
| Richard Lindstrom, M.d, M.D | Ophthalmology | Bloomington, MN | $786,621 | $0 |
| Dr. Lisa Nijm, Md, MD | Ophthalmology | Springfield, IL | $456,529 | $0 |
| Dr. Roy Kline, O.d, O.D | Optometrist | Lake Katrine, NY | $439,717 | $0 |
| Osama Said, O.d, O.D | Corneal and Contact Management | Raleigh, NC | $417,341 | $0 |
| Dr. John Womack, Od, OD | Optometrist | Canton, GA | $414,920 | $0 |
| Dr. Milton Hom, O.d., F.a.a.o, O.D., F.A.A.O | Corneal and Contact Management | Azusa, CA | $394,115 | $0 |
| Dr. Michael Endl, Md, MD | Ophthalmology | Amherst, NY | $375,194 | $0 |
| James Hoffman, O.d, O.D | Optometrist | Orange Park, FL | $362,564 | $0 |
| Ryan Corte, Od, OD | Optometrist | Asheville, NC | $354,281 | $0 |
| Mark Packer, M.d, M.D | Ophthalmology | Boulder, CO | $309,437 | $0 |
| Andrew Von Eschenbach, Md, MD | Urology | Montgomery, TX | $307,992 | $0 |
| Mile Brujic, O.d, O.D | Optometrist | Bowling Green, OH | $276,783 | $0 |
| Jeffrey Lewis, Od, OD | Optometrist | Champaign, IL | $257,638 | $0 |
| Dr. Cathleen Mccabe, M.d, M.D | Ophthalmology | Bradenton, FL | $254,693 | $0 |
| Dr. Carl Awh, M.d, M.D | Ophthalmology | Nashville, TN | $236,997 | $0 |
| Dr. Omid Khodai, O.d, O.D | Optometrist | Lake Forest, CA | $235,913 | $0 |
| Inder Singh | Ophthalmology | Racine, WI | $226,349 | $0 |
| Jason Jedlicka, O.d, O.D | Optometrist | Bloomington, IN | $215,496 | $0 |
| Jamie Kuzniar, O.d, O.D | Optometrist | Bloomfield, MI | $195,139 | $0 |
| Dr. Paul Karpecki, Od, OD | Optometrist | Lexington, KY | $193,247 | $0 |
| Dr. Sheri Rowen, Md, MD | Ophthalmology | Newport Beach, CA | $188,812 | $0 |
| Dr. Jai Parekh, M.d, M.D | Ophthalmology | Woodland Park, NJ | $188,393 | $0 |
| Dr. Richard Yee, Md, MD | Ophthalmology | Bellaire, TX | $182,110 | $0 |
| Mr. Jason Tu, O.d, O.D | Optometrist | San Diego, CA | $179,572 | $0 |
| Dr. Monica Johnsonbaugh, O.d, O.D | Optometrist | Grosse Pointe, MI | $177,792 | $0 |
Ad
Top Products
- INFUSE $6.8M
- MIEBO $6.5M
Associated Products (24)
- INFUSE $11.4M
- MIEBO $6.5M
- enVista MX60 IOL $5.4M
- ATROPINE $1.3M
- XIPERE $1.1M
- ULTRA MULTIFOCAL TORIC $1.0M
- STELLARIS ELITE $1.0M
- ZEN LENS $856,707
- ZENLENS $781,778
- IC-8 Apthera IOL $575,797
- Ophthalmic Instruments $463,658
- enVista Aspire IOL $341,450
- INFUSE MULTIFOCAL $289,558
- Stellaris $152,719
- BLINK NUTRITEARS $145,901
- EUREKA $115,836
- ALDEN SCLERAL ZENLENS $111,754
- Trulign IOL $84,630
- MULTI-FOCAL $48,053
- SOFLENS $34,867
- ENVISTA ENVY $19,350
- CLEARVISC $18,619
- LENSCRAFTERS $18,600
- Boston 7 $14,600
Payment Categories
- Food & Beverage $7.4M
- Consulting $5.6M
- Travel & Lodging $2.1M
- Research $13.3M
- Royalties $2.6M
About Bausch & Lomb Americas Inc.
Bausch & Lomb Americas Inc. has made $43.3M in payments to 35,986 healthcare providers, recorded across 201,802 transactions in the CMS Open Payments database. In 2024, the company paid $15.5M. The top product by payment volume is INFUSE ($6.8M).
Payments were distributed across 123 medical specialties. The top specialty by payment amount is Optometrist ($13.5M to 23,672 doctors).
Payment categories include: Food & Beverage ($7.4M), Consulting ($5.6M), Research ($13.3M), Travel & Lodging ($2.1M), Royalties ($2.6M).
Bausch & Lomb Americas Inc. is associated with 24 products in the CMS Open Payments database, including INFUSE, MIEBO, and enVista MX60 IOL.